A detailed history of Hsbc Holdings PLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 73,126 shares of ALT stock, worth $304,935. This represents 0.0% of its overall portfolio holdings.

Number of Shares
73,126
Previous 85,468 14.44%
Holding current value
$304,935
Previous $330,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025

SELL
$3.38 - $4.76 $41,715 - $58,747
-12,342 Reduced 14.44%
73,126 $275,000
Q2 2025

Aug 13, 2025

BUY
$3.5 - $7.71 $46,235 - $101,849
13,210 Added 18.28%
85,468 $330,000
Q1 2025

May 14, 2025

BUY
$5.0 - $7.45 $361,290 - $538,322
72,258 New
72,258 $361,000
Q3 2020

Nov 12, 2020

SELL
$9.93 - $33.26 $211,767 - $709,302
-21,326 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$2.9 - $10.71 $61,845 - $228,401
21,326 New
21,326 $228,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $204M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.